BioNTech SE American Depositary Share (BNTX) Valuation
Historical valuation analysis based on 1280 data points (2021-09-13 to 2026-10-16)
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including covi...
BioNTech SE American Depositary Share trades near its historical valuation range, with most metrics close to their median levels.
Historical Valuation Metrics
| Metric | Current | Median | %ile | Assessment |
|---|
BioNTech SE American Depositary Share (BNTX) Valuation & P/E History
BioNTech SE American Depositary Share (BNTX) is a US-listed stock operating in the Healthcare sector currently trading at $87.95 with a market capitalization of $22.1 billion. This page provides historical valuation analysis for BNTX based on 1280 data points covering 2021-09-13 to 2026-10-16...
BNTX Valuation Metrics & Historical Range
The valuation table above shows BioNTech SE American Depositary Share's current and historical valuation multiples, including P/E ratio, P/S ratio, EV/EBITDA, FCF yield, and dividend yield. Each metric is compared to its own historical range to determine whether BNTX is currently trading above or below its typical valuation levels.
- P/E ratio: Price-to-earnings measures how much investors pay per dollar of earnings. A P/E above the historical median suggests BNTX is expensively valued; below the median suggests it is cheap.
- P/S ratio: Price-to-sales is useful for companies with volatile or negative earnings. Lower P/S relative to history may indicate value.
- EV/EBITDA: Enterprise value to EBITDA adjusts for debt and cash, providing a capital-structure-neutral valuation measure for BioNTech SE American Depositary Share.
- FCF yield: Free cash flow yield shows the cash return relative to market price. Higher yields may indicate undervaluation.
Is BNTX Overvalued or Undervalued?
BioNTech SE American Depositary Share trades near its historical valuation range, with most metrics close to their median levels. The overall valuation percentile of 50 combines P/E, P/S, and EV/EBITDA percentiles into a single measure of how expensive BNTX is relative to its own history. A percentile below 25 suggests the stock may be undervalued, while a percentile above 75 suggests it may be overvalued.
However, valuation is only one factor in investment decisions. A stock can remain "overvalued" for years if growth accelerates, or "undervalued" if the business deteriorates. Always combine valuation analysis with financial statement analysis and the full BNTX analysis page for a complete picture.
Valuation data is computed from historical price and fundamental data via Polygon.io and Finnhub.BNTX trades on NYSE/NASDAQ. This page is for informational purposes only and is not financial advice.